Technology | Radiation Dose Management | August 19, 2015

Corindus, Unfors Raysafe Partner to Promote Radiation Protection in the Cath Lab

Joint agreement bundles RaySafe i2 real-time radiation dose monitoring system with Corindus’ CorPath vascular robotic system

Corindus, Corpath, radiation dose monitoring, cath lab, vascular robotic system

The Corindus Corpath vascular robotic system.

Unfors RaySafe, RaySafe i2, real-time radiation dose monitoring system

Unfors Raysafe's i2 real-time dose monitoring badge system

August 19, 2015 – Corindus Vascular Robotics Inc. and Unfors RaySafe Inc., a Fluke Biomedical Company, announced a distribution agreement allowing Corindus to offer the RaySafe i2 real-time radiation dose monitoring system in conjunction with the CorPath System. This alignment enables catheterization lab physicians and staff to better protect themselves from, and monitor for, excessive radiation exposure.

The interventional cardiology field is increasingly concerned about the cumulative effects of radiation exposure on physicians and cath lab staff as more studies emerge and stories of individuals who have been forced to leave practice become more prevalent. Top of FormBottom of FormThe The 95 percent radiation exposure reduction afforded by the CorPath System’s radiation shielded cockpit increases protection for interventional cardiologists, while the RaySafe i2 badge worn by cath lab workers displays radiation exposure levels in real-time; this allows the team to be more aware of exposure levels and take steps to minimize exposure, while continuing to deliver a high standard of care.

Spectrum Health System, based in Grand Rapids, Michigan, is one of the first facilities in the United States to install and jointly utilize the CorPath System and RaySafe i2. “We take significant measures to protect our patients, and through the addition of these products, we can do the same for our physicians and cath lab staff,” stated Ryan Madder, M.D., interventional cardiologist at Spectrum Health. “Having integrated the products into my daily practice, I am more aware of both my own exposure levels and that of my team. I appreciate how these technologies can significantly change our behaviors and put us in a safer position to perform procedures.”

For more information: www.corindus.com, www.raysafe.com

Related Content

New Alliance Announced Between Transcatheter Cardiovascular Therapeutics and VEITHsymposium
News | Cath Lab | June 20, 2019
VEITHsymposium and the Cardiovascular Research Foundation (CRF) announced an alliance between Transcatheter...
Novel Index Accurately Predicts PCI Success Post-Procedure Compared to Established Measurement Metrics
News | Cath Lab | June 19, 2019
Results from a comprehensive analysis demonstrate the effectiveness of measuring a non-hyperemic pressure ratio (NHPR...
Philips Healthcare, Volcano IVUS showing an implanted stent. IVUS might offer an alternative to contrast angiography in patients with acute kidney disease (AKD).
News | Cath Lab | June 14, 2019
June 14, 2019 – A late-breaking study examined the effects of intravascular ultrasound (IVUS) guided drug-eluting ste
Videos | Cath Lab | May 20, 2019
This is a walk through of the primary structural heart hybrid cath lab at...
Mobility May Predict Elderly Heart Attack Survivors' Repeat Hospital Stays
News | Cath Lab | April 23, 2019
Determining which elderly heart attack patients take longer to stand from a seated position and walk across a room may...
FDA Releases New Guidance on Medical Devices Containing Nitinol
News | Cath Lab | April 18, 2019
April 18, 2019 — The U.S.
Angiography shows a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL lithoplasty.

Figure 2: Angiography demonstrates a stenotic lesion in the mid right coronary artery, undilatable by standard high-pressure balloon angioplasty (inset, arrowheads). (B) Optical coherence tomography (OCT) cross-sectional (top) and longitudinal (bottom) images acquired before IVL and coregistered to the OCT lens (arrow in A) demonstrate severe near-circumferential calcification (double-headed arrow) in the area of the stenosis. (C) Angiography demonstrates improvement in the area of stenosis after IVL (inset; note the cavitation bubbles generated by IVL [black arrows]). (D) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-IVL and coregistered to the OCT lens (white arrow in C) demonstrate multiple calcium fractures and large acute luminal gain. (E) Angiography demonstrates complete stent expansion with the semicompliant stent balloon (inset) without the need for high-pressure noncompliant balloon inflation. (F) OCT cross-sectional (top) and longitudinal (bottom) images acquired post-stenting and coregistered to the OCT lens (arrow in E) demonstrate further fracture displacement (arrow), with additional increase in the acute area gain (5.17 mm2), resulting in full stent expansion and minimal malapposition.

Feature | Cath Lab | April 15, 2019 | Dean Kereiakes, M.D., FACC, FSCAI, and Jonathan Hill, M.D., DISRUPT CAD III Co-Principal Investigators
Over the last 40 years, despite multiple advancements in percutaneous coronary interventions, calcified lesions remai
BIOTRONIK’s PK Papyrus covered coronary stent. The stent ius used in emergency coronary artery dissections to repair the vessel wall.
Technology | Cath Lab | April 15, 2019
April 15, 2019 — Biotronik began its U.S.
Overlay Init